A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1173-0750

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to confirm that treatment with oral semaglutide does not result in an unacceptable increase in cardiovascular risk compared to placebo (rule out 80% excess risk) in subjects with type 2 diabetes at high risk of cardiovascular events


Critère d'inclusion

  • Diabetes Mellitus, Type 2